Brief: Ose Immunotherapeutics H1 Operating Loss Narrows To EUR 3.4 Mln

Ose Immunotherapeutics SA

22/09/2022 17:54

Sept 22 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS ANNOUNCES CORPORATE UPDATE AND H1
2022
RESULTS
    * €16 MILLION TURNOVER AND €31 MILLION AVAILABLE CASH AS OF
JUNE
30, 2022, PROVIDING FINANCIAL VISIBILITY UNTIL Q3 2023
    * DURING THE FIRST HALF OF 2022, THE COMPANY RECORDED A
CONSOLIDATED NET RESULT OF €-2 MILLION
    * H1 CURRENT OPERATING EXPENSES WERE €19.4 MILLION (VERSUS
€20.6
MILLION FOR THE SAME PERIOD IN 2021) OF WHICH 78% ARE RELATED TO
RESEARCH AND DEVELOPMENT
    * H1 OPERATING LOSS EUR 3.4 MILLION VERSUS LOSS EUR 11.6
MILLION
YEAR AGO

Source text: https://bit.ly/3C2eA3q
Further company coverage:  OSE.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))